Table 1 Demographic, clinical and treatment characteristics of study participants (N = 82)
Demographics | ||
 Male – N (%) | 49 (59.8) | |
 Female | 33 (40.2) | |
 Age in years – Mean (SD), range | 48.67 (8.57), 30–65 | |
 Duration of illness in months – Mean (SD),  range | 204.03 (138.12), 4–720 | |
 Numbers of previous psychiatric admissions –Mean (SD), range | 3.97 (4.17), 0–20 | |
Marital Status – N (%) | ||
 Single | 33 (40.2) | |
 Married | 28 (34.1) | |
 Divorced | 11 (13.4) | |
 Other | 10 (12.3) | |
Educational Level – N (%) | ||
 Primary | 26 (31.7) | |
 Secondary | 44 (53.7) | |
 University/college | 9 (11.0) | |
 None/other | 3 (3.6) | |
Employment Status – N (%) | ||
 Full time | 19 (23.2) | |
 Part time | 5 (6.1) | |
 Unemployed | 40 (48.8) | |
 Other | 18 (22.0) | |
Psychiatric Diagnosis – N (%) | ||
 Schizophrenia | 40 (48.8) | |
 Paranoid schizophrenia | 33 (40.2) | |
 Other psychosis (including  schizoaffective/delusional disorder,  psychosis NOS) | 9 (11.0) | |
Smoking status – N (%) | ||
 Non smoker | 50 (61.0) | |
 Ex-smoker | 1 (1.2) | |
 Light smoker (<10 per day) | 5 (6.1) | |
 Moderate smoker (10–19 per day) | 11 (13.4) | |
 Heavy smoker (≥20 per day) | 15 (18.3) | |
Medication Treatment – N (%) | ||
 Prescribed an antihypertensive | 25 (30.5) | |
 Prescribed a statin | 3 (3.7) | |
 Prescribed diabetes treatment | 7 (8.5) | |
 Prescribed antipsychotic polypharmacy | 28 (34.1) | |
Number of Antipsychotics Prescribed – N (%) | ||
 1 | 54 (65.9) | |
 2 | 24 (29.3) | |
 3 | 4 (4.9) | |
Prescribed psychotropic medications – N (%) | ||
 First Generation Antipsychotics | 35 (42.7) | |
 Second Generation Antipsychotics (all types) | 60 (73.2) | |
  Olanzapine | 16 (19.5) | |
  Risperidone | 9 (11.0) | |
  Paliperidone | 9 (11.0) | |
  Quetiapine | 7 (8.5) | |
  Amisulpride | 4 (4.9) | |
  Aripiprazole | 2 (2.4) | |
  Clozapine | 14 (17.1) | |
 Clozapine and another antipsychotic | 5 (6.1) | |
 First and Second Generation Antipsychotics | 12 (14.6) | |
 Long acting intramuscular antipsychotic injection | 31 (37.8) | |
 Oral antipsychotic and long acting intramuscular injection | 19 (23.2) | |
Mood stabilizer/anti-manic drugs | ||
 Lithium | 3 (3.7) | |
 Sodium valproate | 7 (8.5) | |
 SSRI antidepressant | 2 (2.4) | |
Prescribed Dosage of Antipsychotics | ||
 Cumulative multiples of DDD – Mean (SD), range | 1.62 (1.08), 0.1–5.14 | |
  ≤1.0 DDD – N (%) | 32 (39.0) | |
  1.1–2.0 DDD – N (%) | 26 (31.7) | |
  >2.0 DDD – N (%) | 24 (29.3) | |
Cardiometabolic Health | ||
 BMI (kg/m2) – Mean (SD) | 24.81 (3.73) | |
 BMI underweight – N (%) | 3 (3.7) | |
 BMI healthy – N (%) | 22 (26.8) | |
 BMI overweight – N (%) | 18 (22.0) | |
 BMI obese I – N (%) | 33 (40.2) | |
 BMI obese II – N (%) | 5 (6.1) | |
 Waist circumference obese (≥80 cm  females, ≥90 cm males) – N (%) | 40 (48.8) | |
 Metabolic syndrome (meets IDF criteria)  – N (%) | 24 (29.3) | |
 QRISK®2 10-year CVD risk score – Mean (SD) | 5.28 (5.45) | |
  <10% CVD risk score (low) – N (%) | 71 (86.6) | |
  10–19.9% CVD risk score (moderate) – N (%) | 9 (11.0) | |
  20% + CVD risk score (high) – N (%) | 2 (2.4) | |
  10-year CVD relative risk | – Mean (SD) | 2.80 (2.96) |
– Median (IQR) | 1.80 (1.87) | |
Health-Related Quality of Life | ||
 Physical component score (PCS) – Mean (SD) | 46.01 (7.11) | |
 Mental component score (MCS) – Mean (SD) | 46.93 (9.59) | |